Is Centogene NV overvalued or undervalued?

As of 10 February 2020, Centogene NV's valuation grade has moved from does not qualify to risky, indicating a significant change in its financial outlook. The company appears to be overvalued given its current financial metrics, with a price to book value of -0.15 and an EV to EBITDA ratio of -1.37, both of which suggest severe financial distress. Additionally, the return on capital employed (ROCE) stands at an alarming -253.34%, highlighting the company's inability to generate returns on its capital.
In comparison to its peers, Centogene NV's P/E ratio is -0.0634, while Candel Therapeutics, Inc. has a P/E of -7.3556, and Gaia, Inc. shows a P/E of -21.7073, indicating that Centogene is not the worst performer among its peers but still reflects a troubling valuation. The company's stock has underperformed significantly over the past year, with a return of -62.53% compared to the S&P 500's gain of 10.26%, reinforcing the notion that Centogene NV is overvalued in its current state.